But now the FDA has rubber-stamped the approval of Luxturna, the first ever gene therapy it has backed, all the attention is now on Spark, and what price it plans to charge for the therapy.

The San Diego, Calif.-based firm said Thursday that its Dexcom G7 15 Day system had been approved by the FDA to treat people 18 and older with diabetes. It is expected to launch in the U.S. in the ...